Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Current Press Releases

Webcast ImageWebcast
Q1 2014 Pacira Pharmaceuticals, Inc. Earnings Conference Call (Live)
05/01/14 at 9:00 a.m. ET
Q1 2014 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Thursday, May 1, 2014 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
Recent Press Releases | Archived Press Releases
DateTitle 
04/17/14Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company’s first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/15/14Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4). Pacira granted to 17 new ... 
Printer Friendly Version
04/08/14Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 8, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock at a public offering price of $64.00 per share. After deducting underwriting discounts and commissions and estimated offering expenses, Pacira will receive net proceeds of approximately $96.0 million in the offering. In addition, Pacira has granted the... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it is offering $100 million of its common stock in a proposed underwritten public offering. In addition, Pacira intends to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
New Manufacturing Facility to Meet Future Demand Exceeding the Estimated $400 Million of Current Production Capacity PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced entering into a strategic co-production partnership with Patheon, the pharmaceutical services business owned by DPx Holdings B.V., to manufacture and package EXPAREL® (bupivacaine liposome injectable suspension) a... 
Printer Friendly Version
04/04/14EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
Data Presented at the 39th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine PARSIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Apr. 4, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company ... 
Printer Friendly Version
03/31/14Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL® (bupivacaine liposome injectable suspension). The suite is housed at the company’s Science Center Campus in San Diego, where EXPAREL is currently manufactured. “We believe the approval of an ... 
Printer Friendly Version
03/14/14Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
Data Presented at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons Show EXPAREL Improved Pain Scores, Lowered Opioid Consumption, and Reduced Hospital Stays, Falls and Overall Costs PARSIPPANY, N.J. & NEW ORLEANS--(BUSINESS WIRE)--Mar. 14, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain ... 
Printer Friendly Version
03/06/14Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Yvonne Greenstreet, MBChB, MBA, to its board of directors. “We are delighted to have Yvonne join as our newest board member,” said Dave Stack, president, chief executive officer and chairman of Pacira. “We believe that her vast experience working across a diverse range of critical functions at some of the most est... 
Printer Friendly Version
03/05/14Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
Studies Assess Impact of EXPAREL on Postsurgical Pain and Health Economic Outcomes Following Total Knee and Hip Replacement Procedures PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at... 
Printer Friendly Version
02/27/14Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
sNDA Submission Expected in Second Quarter of 2014 with a 10-month PDUFA Timeline PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. This pivotal Phase 3 trial eval... 
Printer Friendly Version
02/26/14Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 26, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014, at 9 a.m. ET in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be acc... 
Printer Friendly Version
02/25/14Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
PARSIPPANY, N.J., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that a replay of the company's fourth quarter and full-year 2013 financial results conference call, which took place today on Tuesday, February 25, 2014, at 9 a.m. ET, can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international), and providing the Conference ID 16366107. The replay of the call will be available for two weeks from the date of the live call. The... 
Printer Friendly Version
02/25/14Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2013. “We are very pleased with the overall performance and trajectory that we have seen in the ma... 
Printer Friendly Version
02/11/14Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013, will be released before the market opens on Tuesday, February 25, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, February 25, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-07... 
Printer Friendly Version
01/29/14Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 29, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced key findings supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (or iTAP) for postsurgical pain management. A recent independent study led by Andras Sandor, M.D., FACS, FASMBS, chairman of the Department of Surgery and director of the Hallmark H... 
Printer Friendly Version
01/07/14Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
-- Results Reinforce Findings from IMPROVE Trial Series Demonstrating the Opioid-Sparing and Economic Benefits of EXPAREL Compared to Standard Opioid-Based Regimen -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences ... 
Printer Friendly Version
12/05/13Pacira Pharmaceuticals, Inc. Announces Submission of Prior Approval Supplement for Additional EXPAREL® Manufacturing Suite
Anticipated PDUFA Date in Early April 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 5, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has submitted a Prior Approval Supplement (PAS) with the U.S. Food and Drug Administration (FDA) for an additional bulk manufacturing suite for EXPAREL® (bupivacaine liposome injectable suspension). Under the reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA establi... 
Printer Friendly Version
11/25/13Pacira Pharmaceuticals, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013, at 12:30 p.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacir... 
Printer Friendly Version
11/01/13Pacira Pharmaceuticals, Inc. to Present at November Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at investor conferences during November. Mr. Stack will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference on Thursday, November 14, 2013, at 2:40 p.m. ET in ... 
Printer Friendly Version
10/31/13Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9:00 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 31, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the quarter ended September 30, 2013. “The strong third quarter for EXPAREL sales wa... 
Printer Friendly Version
10/17/13Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 17, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2013, will be released before the market opens on Thursday, October 31, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 31, 2013, at 9 a.m. ET. The call... 
Printer Friendly Version
10/01/13Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
Five-year arrangement with CrossLink Bioscience, LLC follows initial pilot program PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the initiation of a five-year promotion arrangement with CrossLink Bioscience, LLC, an orthopedic device distributor based in Atlanta. Under the agreement, CrossLink will act as a local agent as well as a lead partner in current collaboration with... 
Printer Friendly Version
09/19/13Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement
Data Presented at 7th Annual Marshall Steele Orthopedic & Spine Summit PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 19, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results from a 200-patient study evaluating the benefits of EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), commonly known a... 
Printer Friendly Version
09/12/13Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of Directors
Company Founders and Venture Investors Fred Middleton and Luke Evnin to Retire from the Board PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 12, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark A. Kronenfeld, M.D., and Dennis L. Winger to its Board of Directors. Pacira also announced today that Luke Evnin, a managing director at MPM Capital, and Fred Middleton, a general manager at Sanderling Ve... 
Printer Friendly Version
08/06/13Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the quarter ended June 30, 2013. “The second quarter marks the commencement of the secon... 
Printer Friendly Version
08/06/13Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2013 Life Sciences Management Access Conference on Tuesday, August 13, 2013, at 9:45 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
08/01/13EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
Based upon Ongoing Femoral Nerve Block Trial, sNDA Submission Still Planned for Early 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in intercostal nerve block for posterolateral thoracotomy. The study did not achieve its pri... 
Printer Friendly Version
07/30/13Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2013, will be released before the market opens on Tuesday, August 6, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, August 6, 2013, at 9 a.m. ET. The call can be ac... 
Printer Friendly Version
07/18/13New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen
Multicenter study in patients undergoing ileostomy reversal reinforces results from first IMPROVE study in open colectomy PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 18, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the second IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of Pain Research. The IMPROVE studies assess the differences in ... 
Printer Friendly Version
05/29/13Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
Completed Dose Ranging Portion of Pivotal Nerve Block Trial; Phase 3 Initiating; sNDA on Track for Early 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 29, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL® (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block ... 
Printer Friendly Version
05/28/13Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 28, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 10:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be acce... 
Printer Friendly Version
05/08/13Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 5:00 p.m. PT at the Encore at the Wynn in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
05/08/13Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the quarter ended March 31, 2013 and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States. “We saw a solid quarter in what was the fourth quarter ... 
Printer Friendly Version
05/06/13Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control
Data Presented at Annual Meetings of Leading Regional Anesthesia Societies Demonstrate Analgesia for Up to 72 Hours and High Patient Satisfaction PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from two new studies supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane for postsurgical pain managem... 
Printer Friendly Version
05/01/13Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2013, will be released before the market opens on Wednesday, May 8, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, May 8, 2013, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/25/13New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
Retrospective Study Published in Pharmacotherapy Identifies Advanced Age, Obesity, Pre-Surgery Opioid Use and Comorbid Conditions as Predictive Risk Factors for Adverse Events PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 25, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital h... 
Printer Friendly Version